NCT00017680View on ClinicalTrials.gov

Study of High-Dose Melphalan and Autologous Stem Cell Transplantation in Patients With Primary Light Chain Amyloidosis

PHASE2CompletedINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

July 31, 1999

Primary Completion Date

April 30, 2004

Study Completion Date

April 30, 2004

Conditions
Amyloidosis
Interventions
DRUG

Melphalan

100 mg/m2 twice a day from Days -2 and -1 as induction therapy

PROCEDURE

Autologous Stem Cell Transplantation

Bone marrow and peripheral blood stem cells harvested

Trial Locations (1)

10032

Herbert Irving Comprehensive Cancer Center, New York

All Listed Sponsors
lead

Herbert Irving Comprehensive Cancer Center

OTHER

NCT00017680 - Study of High-Dose Melphalan and Autologous Stem Cell Transplantation in Patients With Primary Light Chain Amyloidosis | Biotech Hunter | Biotech Hunter